Drug Trial Radar · NCT03514589
NeSST2: The Development of a Noninvasive Short Synacthen Test
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
182
Actual
Start
Oct 12, 2012
Primary completion
Sep 30, 2026
Study completion Dec 31, 2026
Sponsor
- Lead sponsor
- Sheffield Children's NHS Foundation TrustAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- May 2, 2018
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Diagnostic
- Who can join
- All sexes, up to 17 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Recently there has been concern about the effect of inhaled steroids, routinely used in the treatment of asthma, on the body's ability to produce its natural stress hormone cortisol. Failure of adequate cortisol production in times of stress e.g. illness, can result in serious illness or death. Patients receiving longterm steroid treatment may have reduced levels of cortisol and not be able to produce adequate amounts in times of need, a process called adrenal suppression. Initially it was thought that the absorption of inhaled steroids into the bloodstream would be too low to cause adrenal suppression however high profile deaths followed by a national survey revealed a number of fatal or near fatal cases of adrenal suppression. The vast majority of these were in children. Since then doctors have been encouraged to ensure that children on high doses of inhaled steroids carry a steroid alert card and that the ability of their adrenal glands to produce adequate amounts of cortisol is checked. However it is unknown what dose of inhaled steroids puts one at risk, whether age or gender affects one's risk and when to check the function of the adrenal gland. The Short Synacthen Test (SST) investigates the ability of the body's adrenal glands to produce cortisol. Presently the SST requires intravenous (i.v) cannulation through which Synacthen is injected to stimulate the adrenal glands and multiple blood samples are collected to assess the response in terms of cortisol production. It is invasive, time consuming and unpleasant for the child. Our project aims to produce a noninvasive alternative to the current SST, with Synacthen given nasally and using saliva to measure the subsequent production of cortisol. A noninvasive test will allow us to establish the first normal ranges for children and determine which children with asthma are at risk of adrenal suppression.
Conditions
- Adrenal Suppression
Interventions
nasal TetracosactideDrug
Bioavailability of nasal synacthen compared to IV comparator
IV tetracosactideDrug
Bioavailability of nasal synacthen compared to IV comparator
Primary outcomes
What the sponsor says the trial is designed to measure.
- Peak plasma cortisol concentration (Cmax)Time frame: 6 months
- Time of peak plasma cortisol concentration (Tmax)Time frame: 6 months
- Bioavailability of nasal Synacthen (compared to IV Synacthen)Time frame: 6 months
- Area under the curve for plasma Synacthen (nasal compared to IV)Time frame: 6 months
- Area under the curve for plasma cortisol (nasal compared to IV)Time frame: 6 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Sheffield Children's NHS Foundation Trust
Sheffield, Sheffield (South Yorkshire District), United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.